Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Prostatic Neoplasms 26Lymphoma, Large B-Cell, Diffuse 15Lymphoma 14Burkitt Lymphoma 10Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Follicular 7Lymphoma, B-Cell 7Hodgkin Disease 6Lymphoma, Non-Hodgkin 4Recurrence 3Prostatic Neoplasms, Castration-Resistant 3Leukemia 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2Melanoma 2Lymphoproliferative Disorders 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, AIDS-Related 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Biphenotypic, Acute 2Immunoblastic Lymphadenopathy 2Vasculitis, Central Nervous System 1Urogenital Neoplasms 1Stiff-Person Syndrome 1Stage II Prostate Adenocarcinoma 1Skin Neoplasms 1Rasmussen subacute encephalitis 1Prostate Cancer, Hereditary, 7 1

Interventions

Infliximab 2vedolizumab 1Prednisone 1Methylprednisolone Hemisuccinate 1Methylprednisolone 1LDP-02 1Immunoglobulin G 1Disulfides 1CT-P13 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Colitis × Prednisone × Clear all
NCT04305145 2026-01-29

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Massachusetts General Hospital

Phase 2 Active not recruiting
42 enrolled
Dermatologic

Colitis, Melanoma, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡